Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Hematopoietic and Lymphatic System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm

Cancer Family

Hematopoietic and Lymphatic System Neoplasm

CI-CAN-00000022Explore in graph →

Non-malignant4,304 active trials98 approved drugs1,010 evidence items

NCIt: C35813

Overview
Statistics
Survival
Genomics60
Variants & evidence1010
Drugs99
Trials18827
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (736)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 501–525 of 736 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.
· Blood · 2015 · PMID 26268241 · validated civic_curation pubmed
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
· Nat Genet · 2013 · PMID 23222956 · validated civic_curation pubmed
Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients.
· Korean J Hematol · 2011 · PMID 21461300 · validated civic_curation pubmed
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
· Leukemia · 2011 · PMID 21415852 · validated civic_curation pubmed
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
· J Clin Oncol · 2010 · PMID 20733134 · validated civic_curation pubmed
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.
· Blood · 2005 · PMID 16046528 · validated civic_curation pubmed
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
· Blood · 2011 · PMID 22031865 · validated

Showing 501–525 of 736 publications

← Previous
1
…
20
21
22
…
30
Next →

civic_curation

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

· N Engl J Med · 2013 · PMID 23656643 · validated civic_curation pubmed

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.

· Blood · 1993 · PMID 8241511 · validated civic_curation pubmed

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

· J Clin Oncol · 2011 · PMID 21483000 · validated civic_curation pubmed

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.

· Blood · 2015 · PMID 26124496 · validated civic_curation pubmed

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

· Leukemia · 2016 · PMID 27137476 · validated civic_curation pubmed

Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.

· Cancer Res · 1998 · PMID 9788599 · validated civic_curation pubmed

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

· Leukemia · 2012 · PMID 22124213 · validated civic_curation pubmed

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.

· Blood · 2016 · PMID 27226433 · validated civic_curation pubmed

ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.

· Haematologica · 2012 · PMID 21993670 · validated civic_curation pubmed

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

· Nat Med · 2015 · PMID 26193344 · validated civic_curation pubmed

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

· Clin Cancer Res · 2016 · PMID 26459177 · validated civic_curation pubmed

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

· Blood · 2015 · PMID 25452615 · validated civic_curation pubmed

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

· Blood · 2011 · PMID 21865346 · validated civic_curation pubmed

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

· J Clin Oncol · 2009 · PMID 19652056 · validated civic_curation pubmed

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

· Blood · 2012 · PMID 22371878 · validated civic_curation pubmed

Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.

· Proc Natl Acad Sci U S A · 2018 · PMID 30487223 · validated civic_curation pubmed

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.

· Blood Adv · 2018 · PMID 29507076 · validated civic_curation pubmed

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.

· Blood Adv · 2020 · PMID 32589730 · validated civic_curation pubmed